Discovery and characterization of AZ6197, a potent and selective ERK1/2 inhibitor

被引：0

作者：

Flemington, Vikki ^{[1
]}

Simpson, Iain ^{[1
]}

Davies, Emma ^{[1
]}

Robinson, David ^{[1
]}

Lindsay, Nicola ^{[1
]}

Hanson, Lyndsey ^{[1
]}

Hopcroft, Philip ^{[1
]}

Tonge, Michael ^{[1
]}

Roberts, Karen ^{[1
]}

Ward, Richard ^{[1
]}

机构：

[1] AstraZeneca, Cambridge, England

来源：

MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期

关键词：

D O I：

10.1158/1535-7163.TARG-17-B156

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B156

引用

页数：2

共 50 条

[1] Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development
Robarge, Kirk
Schwarz, Jacob
Blake, Jim
Burkard, Michael
Chan, Jocelyn
Chen, Huifen
Chou, Kang-Jye
Diaz, Dolores
Gaudino, John
Gould, Stephen
Grina, Jonas
Xin Linghu
Liu, Lichuan
Martinson, Matthew
Moreno, David A.
Orr, Christine
Pacheco, Patricia
Qin, Ann
Rasor, Kevin
Ren, Li
Shahidi-Latham, Sheerin
Stults, Jeffrey
Sullivan, Francis
Wang, Weiru
Yin, Peter
Zhou, Aihe
Belvin, Marcia
Merchant, Mark
Moffat, John G.
[J]. CANCER RESEARCH, 2014, 74 (19)
[2] Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development
Schwarz, Jacob
Blake, James
Burkard, Michael
Chan, Jocelyn
Chen, Huifen
Chou, Kang-Jye
Diaz, Dolores
Dudley, Danette
Gaudino, John
Gould, Stephen
Grina, Jonas
Hunsaker, Thomas
Liu, Lichuan
Martinson, Matthew
Moreno, David
Orr, Christine
Pacheco, Patricia
Qin, Ann
Rasor, Kevin
Ren, Li
Robarge, Kirk
Shahidi-Latham, Sheerin
Stults, Jeffrey
Sullivan, Francis
Wang, Weiru
Yin, Jianping
Zhou, Aihe
Belvin, Marcia
Merchant, Mark
Moffat, John
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
[3] Discovery of potent and selective inhibitors of ERK1/2 with a unique mechanism of action
Deng, Yongqi
Samatar, Ahmed
Shipps, Gerald
Cooper, Alan
Long, Brian
Carr, Donnar
Xiao, Li
Hruza, Alan
Wang, Tong
Zhu, Liang
Nan, Yang
Patel, Mehul
Muppalla, Kiran
Zhu, Hugh
Boga, Babu Sobhana
Gao, Xiaolei
[J]. CANCER RESEARCH, 2016, 76
[4] Discovery of Highly Potent, Selective, and Efficacious Small Molecule Inhibitors of ERK1/2
Ren, Li
Grina, Jonas
Moreno, David
Blake, James F.
Gaudino, John J.
Garrey, Rustam
Metcalf, Andrew T.
Burkard, Michael
Martinson, Matthew
Rasor, Kevin
Chen, Huifen
Dean, Brian
Gould, Stephen E.
Pacheco, Patricia
Shahidi-Latham, Sheerin
Yin, Jianping
West, Kristina
Wang, Weiru
Moffat, John G.
Schwarz, Jacob B.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (04) : 1976 - 1991
[5] Discovery and characterization of AZ285 as a potent and selective inhibitor of CK2 kinase
Dowling, James E.
Alimzhanov, Marat
Bao, Larry
Brassil, Patrick
Cooke, Emma L.
Denz, Christopher R.
Liu, Zhong-Ying
Ye, Qing
Lyne, Paul D.
[J]. CANCER RESEARCH, 2012, 72
[6] Fragment-based discovery of a highly potent, orally bioavailable ERK1/2 inhibitor that modulates the phosphorylation and catalytic activity of ERK1/2
Heightman, Tom D.
Berdini, Valerio
Braithwaite, Hannah
Buck, Ildiko
Cassidy, Megan
Castro, Juan
Courtin, Aurelie
Day, James
East, Charlotte
Fazal, Lynsey
Graham, Brent
Griffiths-Jones, Charlotte
Lyons, John
Martins, Vanessa
Muench, Sandra
Munck, Joanne
Norton, David
O'Reilly, Marc
Palmer, Nick
Pathuri, Puja
Reader, Mike
Rees, David
Rich, Sharna
Richardson, Caroline
Saini, Harpreet
Thompson, Neil
Wallis, Nicola
Walton, Hugh
Wilsher, Nicola
Woolford, Alison
Murray, Chris
[J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
[7] Preclinical characterization of HMPL-295, a potent and selective ERK 1/2 inhibitor
Hu, Jia
Ni, Jun
Lv, Yuanzhi
Li, Wenjun
Zhang, Hui
Li, Xin
Yu, Ying
Zhong, Zeyu
Wang, Jian
Sai, Yang
Qing, Weiguo
Ren, Yongxin
Shi, Michael
Su, Weiguo
[J]. CANCER RESEARCH, 2024, 84 (06)
[8] Discovery of AZD0364, a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC
Simpson, Iain
Anderton, Mark J.
Andrews, David M.
Breed, Jason
Davies, Emma
Debreczeni, Judit E.
Flemington, Vikki
Gibbons, Francis D.
Graham, Mark A.
Hopcroft, Philip
Howard, Tina
Hudson, Julian
Jones, Clifford D.
Jones, Christopher
Lindsay, Nicola
Pease, J. Elizabeth
Rawlins, Philip
Roberts, Karen
Swallow, Steve
St-Gallay, Steve
Tonge, Michael E.
Ward, Richard A.
[J]. CANCER RESEARCH, 2018, 78 (13)
[9] Discovery of LY3214996, a selective and novel ERK1/2 inhibitor with potent antitumor activities in cancer models with MAPK pathway alterations
Bhagwat, Shripad V.
McMillen, William T.
Cai, Shufen
Zhao, Baohui
Whitesell, Matthew
Kindler, Lisa
Flack, Robert S.
Wu, Wenjuan
Huss, Karen
Anderson, Bryan
Yuan, Xiu-Juan
Jaken, Susan
McCann, Denis
Mathes, Brian
Dropsey, Andrew J.
Manro, Jason
Walgren, Jennie
Yuen, Eunice
Gong, Xueqian
Rodriguez, Michael J.
Huang, Jianping
Tiu, Ramon V.
Joseph, Sajan
Peng, Sheng-Bin
[J]. CANCER RESEARCH, 2017, 77
[10] Characterization of a novel ERK1/2 inhibitor, which modulates the phosphorylation and catalytic activity of ERK1/2
Munck, Joanne M.
Berdini, Valerio
Bevan, Luke D.
Braithwaite, Hannah
Buck, Ildiko M.
Cassidy, Megan
Castro, Juan
Courtin, Aurelie
Day, James E.
East, Charlotte
Fazal, Lynsey
Graham, Brent
Griffiths-Jones, Charlotte M.
Heightman, Tom D.
Hindley, Chris J.
Kidane, Birikiti
Kucia-Tran, Justyna
Lyons, John F.
Martins, Vanessa
Muench, Sandra
Murray, Chris W.
Norton, David
O'Reilly, Marc
Palmer, Nick
Pathuri, Puja
Reader, Mike
Rees, David C.
Rich, Sharna J.
Richardson, Caroline J.
Saini, Harpreet K.
Shah, Alpesh
Stanczuk, Lukas
Thompson, Neil T.
Walton, Hugh
Wilsher, Nicola E.
Woolford, Alison J.
Wallis, Nicola G.
[J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)

← 1 2 3 4 5 →